期刊
HUMAN PATHOLOGY
卷 72, 期 -, 页码 28-34出版社
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.humpath.2017.08.010
关键词
Breast cancer; Invasive ductal carcinoma; Programmed cell death ligand-1; lmmunohistochemistry; Comparative analysis; Three antibodies
类别
The interaction of programmed cell death-1 and its ligand-1 (PD-L1) serves as a regulatory check against excessive immune response to antigen and autoimmunity. We compared the performance of 3 different PD-L1 antibodies (Ventana SP263, Dako 22C3, and BioCare RbMCAL10 antibodies) in 136 invasive ductal carcinoma specimens including 43 primary, 48 locally metastatic, and 46 distantly metastatic diseases. PD-L1 expression was correlated with clinicopathologic parameters including tumor size, grade, lymphovascular invasion, estrogen receptor, progesterone receptor, HER2, Ki67, molecular type, and triple-negative status. There was excellent agreement between the 3 antibodies, with highly significant kappa values (P <= .001). PD-L1 expression was more likely to be associated with higher tumor grade and estrogen receptor negative, progesterone receptor negative, triple-negative, and highly proliferative tumors (P <= .001). When we studied PD-L1 expression at 0, 1%-9%, 10%-49%, and >= 50% cutoff points by the 3 antibodies, there were 20 discordant cases between the antibodies. Sixteen were of inconsequential impact as far as low and high PD-L1 expression. The 4 differences between antibodies did exhibit an interesting pattern of expression, where there was a general agreement between the BioCare and Ventana antibodies with consistently higher PD-L1 expression compared with the Dako antibody. Given the high concordance, it is not surprising that all 3 antibodies demonstrated the same associations with all pathologic and clinical parameters studied. Standardization studies to identify reliable biomarkers that help in patient selection for immune therapy to improve the risk-benefit ratio for these drugs are still needed. (C) 2017 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据